<DOC>
	<DOCNO>NCT02306590</DOCNO>
	<brief_summary>The primary objective trial investigate survival time ( time randomization death date end study ) compare control group experimental group . This prospective , multicenter , randomize , stratify , parallel-group , double-blind trial compare placebo high caloric fatty diet drink add-on therapy 100 mg riluzole amyotrophic lateral sclerosis ( ALS ) 200 enrolled patient . For entry , El Escorial Criteria diagnosis ALS use . The patient stable riluzole least 4 week prior randomization .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability High Lipid Calorie Supplementation Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Possible , probable ( clinically laboratory support ) definite ALS accord revise version El Escorial criterion ( Brooks et al . 2000 ) Disease duration &lt; 36 month Vital capacity 50 % normal ( defined slow vital capacity , best three measurement ) Age â‰¥18 year Continuously treat 100 mg riluzole daily least four week Capable thoroughly understand information give give full inform consent accord GCP Willing complete diet questionnaire throughout participation study Simultaneous participation another interventional clinical study Previous participation drug clinical trial last intake trial drug within last 12 week Known sensitivity intolerance rape oil sunflower oil , component thereof Tracheostomy Patients gastrostomy Pregnancy breastfeed Any medical condition know association motor neuron dysfunction might confound obscure diagnosis ALS Presence concomitant lifethreatening disease impairment likely interfere functional assessment . Evidence major psychiatric disorder clinically evident dementia preclude evaluation symptom . Liable cooperative comply study requirement assess investigator , unable reach case emergency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>survival time</keyword>
	<keyword>ALS Functional Rating Scale</keyword>
	<keyword>quality life</keyword>
	<keyword>survival</keyword>
</DOC>